Causes and consequences of coagulation activation in sepsis: An evolutionary medicine perspective

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  Fiusa, Maiara Marx Luz ^a   Carvalho Filho, Marco Antonio ^a   Annichino Bizzacchi, Joyce M ^a   De Paula, Erich V ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5 LEIDEN; DROTRECOGIN; FIBRIN; KININOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEINASE ACTIVATED RECEPTOR; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; STREPTOKINASE; WARFARIN;

ARTICLE; BACTERIAL VIRULENCE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; DISEASE SEVERITY; DRUG MECHANISM; EVOLUTION; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INFLAMMATION; INNATE IMMUNITY; KNG1 GENE; LEUKOCYTE; LISTERIOSIS; MORTALITY; NONHUMAN; PATHOGEN CLEARANCE; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; RISK FACTOR; SEPSIS; STREPTOCOCCUS PYOGENES; THROMBOCYTE COUNT; THROMBOEMBOLISM; WOUND HEALING; YERSINIA PESTIS; ANIMAL; COMPLICATION; IMMUNOLOGY; PHYSIOLOGY;

ANIMALS; BIOLOGICAL EVOLUTION; BLOOD COAGULATION; HUMANS; IMMUNITY, INNATE; SEPSIS;

EID: 84928812293     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-015-0327-2     Document Type: Article

References (91)

1. Vincent J-L, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet. 2013;381:774-5.
2. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013;41:1167-74.
3. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840-51.
4. Wiersinga WJ, Leopold SJ, Cranendonk DR, van der Poll T. Host innate immune responses to sepsis. Virulence. 2014;5:36-44.
5. Salomao R, Brunialti MKC, Rapozo MM, Baggio-Zappia GL, Galanos C, Freudenberg M. Bacterial sensing, cell signaling, and modulation of the immune response during sepsis. Shock. 2012;38:227-42.
6. Chen GY, Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010;10:826-37.
7. Hansen JD, Vojtech LN, Laing KJ. Sensing disease and danger: a survey of vertebrate PRRs and their origins. Dev Comp Immunol. 2011;35:886-97.
8. Barreiro LB, Quintana-Murci L. From evolutionary genetics to human immunology: how selection shapes host defence genes. Nat Rev Genet. 2010;11:17-30.
9. Quach H, Wilson D, Laval G, Patin E, Manry J, Guibert J, et al. Different selective pressures shape the evolution of Toll-like receptors in human and African great ape populations. Hum Mol Genet. 2013;22:4829-40.
10. Laayouni H, Oosting M, Luisi P, Ioana M, Alonso S, Ricaño-Ponce I, et al. Convergent evolution in European and Rroma populations reveals pressure exerted by plague on Toll-like receptors. Proc Natl Acad Sci U S A. 2014;111:2668-73.
11. Pino-Yanes M, Corrales A, Casula M, Blanco J, Muriel A, Espinosa E, et al. Common variants of TLR1 associate with organ dysfunction and sustained pro-inflammatory responses during sepsis. PLoS One. 2010;5:e13759.
12. Seeley EJ, Matthay MA, Wolters PJ. Inflection points in sepsis biology: from local defense to systemic organ injury. Am J Physiol Lung Cell Mol Physiol. 2012;303:L355-63.
13. Areal H, Abrantes J, Esteves PJ. Signatures of positive selection in Toll-like receptor (TLR) genes in mammals. BMC Evol Biol. 2011;11:368.
14. Davidson CJ, Tuddenham EG, McVey JH. 450 million years of hemostasis. J Thromb Haemost. 2003;1:1487-94.
15. Loof TG, Mörgelin M, Johansson L, Oehmcke S, Olin AI, Dickneite G, et al. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood. 2011;118:2589-98.
16. Monahan-Earley R, Dvorak AM, Aird WC. Evolutionary origins of the blood vascular system and endothelium. J Thromb Haemost. 2013;11:46-66.
17. Aird WC. Endothelial cell heterogeneity. Cold Spring Harb Perspect Med. 2012;2:a006429.
18. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med. 1999;340:1555-64.
19. Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care. 2003;7:23-38.
20. Opal SM. Phylogenetic and functional relationships between coagulation and the innate immune response. Crit Care Med. 2000;28:S77-80.
21. Diamond JM. Guns, germs, and steel: the fates of human societies. New York, NY, USA: W. W. Norton and Company; 1999. p. 496.
22. Antón SC, Potts R, Aiello LC. Human evolution. Evolution of early Homo: an integrated biological perspective. Science. 2014;345:1236828.
23. Terio KA, Kinsel MJ, Raphael J, Mlengeya T, Lipende I, KirchhoffCA, et al. Pathologic lesions in chimpanzees (Pan trogylodytes schweinfurthii) from Gombe National Park, Tanzania, 2004-2010. J Zoo Wildl Med. 2011;42:597-607.
24. Semple S, Cowlishaw G, Bennett PM. Immune system evolution among anthropoid primates: parasites, injuries and predators. Proc Biol Sci. 2002;269:1031-7.
25. Alcock J, Brainard AH. Hemostatic containment - an evolutionary hypothesis of injury by innate immune cells. Med Hypotheses. 2008;71:960-8.
26. Lee PY, Yun AJ, Bazar KA. Acute coronary syndromes and heart failure may reflect maladaptations of trauma physiology that was shaped during pre-modern evolution. Med Hypotheses. 2004;62:861-7.
27. Van Mens TE, Levi M, Middeldorp S. Evolution of Factor V Leiden. Thromb Haemost. 2013;110:23-30.
28. Cagliani R, Forni D, Riva S, Pozzoli U, Colleoni M, Bresolin N, et al. Evolutionary analysis of the contact system indicates that kininogen evolved adaptively in mammals and in human populations. Mol Biol Evol. 2013;30:1397-408.
29. Opal SM, Dellinger RP, Vincent J-L, Masur H, Angus DC. The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C? Crit Care Med. 2014;42:1714-21.
30. Levi M, Keller TT, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res. 2003;60:26-39.
31. Pawlinski R, Pedersen B, Schabbauer G, Tencati M, Holscher T, Boisvert W, et al. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood. 2004;103:1342-7.
32. Xu H, Ploplis VA, Castellino FJ. A coagulation factor VII deficiency protects against acute inflammatory responses in mice. J Pathol. 2006;210:488-96.
33. Jiang L, Jiang S, Feng X, Ma Y, Zhang M. The efficacy and safety of different anticoagulants on patients with severe sepsis and derangement of coagulation: a protocol for network meta-analysis of randomised controlled trials. BMJ Open. 2014;4:e006770.
34. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013;110:3507-12.
35. Shimamura K, Oka K, Nakazawa M, Kojima M. Distribution patterns of microthrombi in disseminated intravascular coagulation. Arch Pathol Lab Med. 1983;107:543-7.
36. Kojima M, Shimamura K, Mori N, Oka K, Nakazawa M. A histological study on microthrombi in autopsy cases of DIC. Bibl Haematol. 1983;49:95-106.
37. Tajiri T, Tate G, Masunaga A, Miura K, Masuda S, Kunimura T, et al. Autopsy cases of fulminant bacterial infection in adults: clinical onset depends on the virulence of bacteria and patient immune status. J Infect Chemother. 2012;18:637-45.
38. Tajiri T, Tate G, Enosawa T, Akita H, Ohike N, Masunaga A, et al. Clinicopathological findings in fulminant-type pneumococcal infection: report of three autopsy cases. Pathol Int. 2007;57:606-12.
39. Donzé JD, Ridker PM, Finlayson SRG, Bates DW. Impact of sepsis on risk of postoperative arterial and venous thromboses: large prospective cohort study. BMJ. 2014;349:g5334.
40. Ribeiro DD, Lijfering WM, Van Hylckama VA, Rosendaal FR, Cannegieter SC. Pneumonia and risk of venous thrombosis: results from the MEGA study. J Thromb Haemost. 2012;10:1179-82.
41. Picoli-Quaino SK, Alves BE, Faiotto VB, Montalvao SAL, De Souza CA, Annichino-Bizzacchi JM, et al. Impairment of thrombin generation in the early phases of the host response of sepsis. J Crit Care. 2014;29:31-6.
42. Massion PB, Peters P, Ledoux D, Zimermann V, Canivet J-L, Massion PP, et al. Persistent hypocoagulability in patients with septic shock predicts greater hospital mortality: impact of impaired thrombin generation. Intensive Care Med. 2012;38:1326-35.
43. Brüne M, Hochberg Z. Evolutionary medicine - the quest for a better understanding of health, disease and prevention. BMC Med. 2013;11:116.
44. Van der Poll T, Herwald H. The coagulation system and its function in early immune defense. Thromb Haemost. 2014;112:640-8.
45. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13:34-45.
46. Ruf W. Protease-activated receptor signaling in the regulation of inflammation. Crit Care Med. 2004;32:S287-92.
47. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3:1800-14.
48. Mackman N. The many faces of tissue factor. J Thromb Haemost. 2009;7:136-9.
49. Nickel KF, Renné T. Crosstalk of the plasma contact system with bacteria. Thromb Res. 2012;130 Suppl :S78-83.
50. Mullarky IK, Szaba FM, Berggren KN, Parent MA, Kummer LW, Chen W, et al. Infection-stimulated fibrin deposition controls hemorrhage and limits hepatic bacterial growth during listeriosis. Infect Immun. 2005;73:3888-95.
51. Luo D, Szaba FM, Kummer LW, Plow EF, Mackman N, Gailani D, et al. Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium Yersinia enterocolitica. J Immunol. 2011;187:1866-76.
52. Sun H, Wang X, Degen JL, Ginsburg D. Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood. 2009;113:1358-64.
53. Loof TG, Schmidt O, Herwald H, Theopold U. Coagulation systems of invertebrates and vertebrates and their roles in innate immunity: the same side of two coins? J Innate Immun. 2011;3:34-40.
54. Van Deventer SJ, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990;76:2520-6.
55. Biemond BJ, Levi M, Ten Cate H, Van der Poll T, Büller HR, Hack CE, et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci (Lond). 1995;88:587-94.
56. Kager LM, Wiersinga WJ, Roelofs JJTH, Meijers JCM, Levi M, Van't Veer C, et al. Endogenous tissue-type plasminogen activator impairs host defense during severe experimental Gram-negative sepsis (melioidosis)*. Crit Care Med. 2012;40:2168-75.
57. Kager LM, Wiersinga WJ, Roelofs JJTH, Meijers JCM, Levi M, Van't Veer C, et al. Plasminogen activator inhibitor type I contributes to protective immunity during experimental Gram-negative sepsis (melioidosis). J Thromb Haemost. 2011;9:2020-8.
58. Lim JH, Woo C-H, Li J-D. Critical role of type 1 plasminogen activator inhibitor (PAI-1) in early host defense against nontypeable Haemophilus influenzae (NTHi) infection. Biochem Biophys Res Commun. 2011;414:67-72.
59. Kager LM, Weehuizen TA, Wiersinga WJ, Roelofs JJTH, Meijers JCM, Dondorp AM, et al. Endogenous aα2-antiplasmin is protective during severe gram-negative sepsis (melioidosis). Am J Respir Crit Care Med. 2013;188:967-75.
60. Bergmann S, Hammerschmidt S. Fibrinolysis and host response in bacterial infections. Thromb Haemost. 2007;98:512-20.
61. Loof TG, Deicke C, Medina E. The role of coagulation/fibrinolysis during Streptococcus pyogenes infection. Front Cell Infect Microbiol. 2014;4:128.
62. Lathem WW, Price PA, Miller VL, Goldman WE. A plasminogen-activating protease specifically controls the development of primary pneumonic plague. Science. 2007;315:509-13.
63. Sodeinde OA, Subrahmanyam YV, Stark K, Quan T, Bao Y, Goguen JD. A surface protease and the invasive character of plague. Science. 1992;258:1004-7.
64. Enz Hubert RM, Rodrigues MV, Andreguetto BD, Santos TM, de Fátima Pereira Gilberti M, de Castro V, et al. Association of the immature platelet fraction with sepsis diagnosis and severity. Sci Rep. 2015;5:8019.
65. Wong CHY, Jenne CN, Petri B, Chrobok NL, Kubes P. Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance. Nat Immunol. 2013;14:785-92.
66. De Stoppelaar SF, van't Veer C, Claushuis TAM, Albersen BJA, Roelofs JJTH, van der Poll T. Thrombocytopenia impairs host defense in gram-negative pneumonia derived sepsis. Blood. 2014;124:3781-90.
67. Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood. 2013;123:2768-76.
68. Yipp BG, Kubes P. NETosis: how vital is it? Blood. 2013;122:2784-94.
69. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med. 2007;13:463-9.
70. Luo D, Szaba FM, Kummer LW, Johnson LL, Tucker EI, Gruber A, et al. Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis. Infect Immun. 2012;80:91-9.
71. Tucker EI, Gailani D, Hurst S, Cheng Q, Hanson SR, Gruber A. Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis. J Infect Dis. 2008;198:271-4.
72. Flick MJ, Du X, Prasad JM, Raghu H, Palumbo JS, Smeds E. Genetic elimination of the binding motif on fibrinogen for the S. aureus virulence factor ClfA improves host survival in septicemia. Blood. 2013;121:1783-94.
73. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238-47.
74. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869-78.
75. Ranieri VM, Thompson BT, Barie PS, Dhainaut J-F, Douglas IS, Finfer S, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055-64.
76. Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, et al. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood. 2003;102:3085-92.
77. De Backer D, Verdant C, Chierego M, Koch M, Gullo A, Vincent J-L. Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis. Crit Care Med. 2006;34:1918-24.
78. Donati A, Damiani E, Botticelli L, Adrario E, Lombrano MR, Domizi R, et al. The aPC treatment improves microcirculation in severe sepsis/septic shock syndrome. BMC Anesthesiol. 2013;13:25.
79. Kalil AC, LaRosa SP. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. Lancet Infect Dis. 2012;12:678-86.
80. Iba T, Saitoh D, Wada H, Asakura H. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey. Crit Care. 2014;18:497.
81. Schouten M, de Boer JD, Kager LM, Roelofs JJTH, Meijers JCM, Esmon CT, et al. The endothelial protein C receptor impairs the antibacterial response in murine pneumococcal pneumonia and sepsis. Thromb Haemost. 2014;111:970-80.
82. Kager LM, Schouten M, Wiersinga WJ, de Boer JD, Lattenist LCW, Roelofs JJTH, et al. Overexpression of the endothelial protein C receptor is detrimental during pneumonia-derived gram-negative sepsis (Melioidosis). PLoS Negl Trop Dis. 2013;7:e2306.
83. Zheng X, Li W, Song Y, Hu Y, Ferrell GL, Esmon NL, et al. Non-hematopoietic EPCR regulates the coagulation and inflammatory responses during endotoxemia. J Thromb Haemost. 2007;5:1394-400.
84. Renckens R, Roelofs JJTH, Florquin S, de Vos AF, Pater JM, Lijnen HR, et al. Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice. J Immunol. 2006;177:1189-96.
85. Vancine SMC, Picoli-Quaino SK, Costa DSP, Montalvao SAL, Ozelo MC, Annichino-Bizzacchi JM, et al. Evaluation of the host response to endotoxemia of FVIII and FIX deficient mice. Haemophilia. 2011;17:800-7.
86. Schoenmakers SHHF, Brüggemann LW, Groot AP, Maijs S, Reitsma PH, Spek CA. Role of coagulation FVIII in septic peritonitis assessed in hemophilic mice. J Thromb Haemost. 2005;3:2738-44.
87. Renckens R, Roelofs JJTH, Bonta PI, Florquin S, de Vries CJM, Levi M, et al. Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia. Blood. 2007;109:1593-601.
88. Schoenmakers SHHF, Versteeg HH, Groot AP, Reitsma PH, Spek CA. Tissue factor haploinsufficiency during endotoxin induced coagulation and inflammation in mice. J Thromb Haemost. 2004;2:2185-93.
89. Levi M, Dörffler-Melly J, Reitsma P, Buller H, Florquin S, van der Poll T, et al. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood. 2003;101:4823-7.
90. Renckens R, Roelofs JJTH, ter Horst SAJ, van't Veer C, Havik SR, Florquin S, et al. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol. 2005;175:6764-71.
91. Brüggemann LW, Schoenmakers SHHF, Groot AP, Reitsma PH, Spek CA. Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice. Crit Care Med. 2006;34:2201-6.